1. Home
  2. PULM vs BOLD Comparison

PULM vs BOLD Comparison

Compare PULM & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PULM
  • BOLD
  • Stock Information
  • Founded
  • PULM 2003
  • BOLD 2018
  • Country
  • PULM United States
  • BOLD United States
  • Employees
  • PULM N/A
  • BOLD N/A
  • Industry
  • PULM Biotechnology: Pharmaceutical Preparations
  • BOLD
  • Sector
  • PULM Health Care
  • BOLD
  • Exchange
  • PULM Nasdaq
  • BOLD Nasdaq
  • Market Cap
  • PULM 20.5M
  • BOLD 24.4M
  • IPO Year
  • PULM N/A
  • BOLD 2024
  • Fundamental
  • Price
  • PULM $5.57
  • BOLD $1.19
  • Analyst Decision
  • PULM
  • BOLD Buy
  • Analyst Count
  • PULM 0
  • BOLD 3
  • Target Price
  • PULM N/A
  • BOLD $4.00
  • AVG Volume (30 Days)
  • PULM 10.9K
  • BOLD 105.1K
  • Earning Date
  • PULM 08-12-2025
  • BOLD 08-11-2025
  • Dividend Yield
  • PULM N/A
  • BOLD N/A
  • EPS Growth
  • PULM N/A
  • BOLD N/A
  • EPS
  • PULM N/A
  • BOLD N/A
  • Revenue
  • PULM $1,921,000.00
  • BOLD N/A
  • Revenue This Year
  • PULM N/A
  • BOLD N/A
  • Revenue Next Year
  • PULM $134.88
  • BOLD N/A
  • P/E Ratio
  • PULM N/A
  • BOLD N/A
  • Revenue Growth
  • PULM N/A
  • BOLD N/A
  • 52 Week Low
  • PULM $1.78
  • BOLD $1.00
  • 52 Week High
  • PULM $10.40
  • BOLD $4.72
  • Technical
  • Relative Strength Index (RSI)
  • PULM 36.25
  • BOLD N/A
  • Support Level
  • PULM $5.20
  • BOLD N/A
  • Resistance Level
  • PULM $6.15
  • BOLD N/A
  • Average True Range (ATR)
  • PULM 0.30
  • BOLD 0.00
  • MACD
  • PULM -0.05
  • BOLD 0.00
  • Stochastic Oscillator
  • PULM 22.70
  • BOLD 0.00

About PULM Pulmatrix Inc.

Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).

About BOLD Boundless Bio Inc. Common Stock

Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

Share on Social Networks: